New Cosmetics In Brief: P&G’s DUO Buffers; Clinique Anti-Aging Booster; Lime Crime Pop On Nails; More

P&G and Unilever/Dove launch new shower items for body cleansing and dandruff treatment, respectively; Meanwhile, new Clinique Fresh Pressed Daily Booster rejuvenates skin when added to users’ routine moisturizers. More on recent cosmetic launches.

Procter & Gamble Co. is touting its new DUO dual-sided body cleansing buffers – available across the firm’s Olay, Old Spice and Ivory brands – as “the first new cleansing form to be introduced in 20 years based on evolving customer habits.” According to a 2015 study, 44% of women and 34% of men say they use both a bar and body wash in the shower to ensure that their skin is getting both a deep, exfoliating clean and a soft, nourishing treatment. Designed to streamline such routines, the DUO line “unites the clean of a bar, the care of a body wash and the experience of a puff to give users a multi-sensory, best of all worlds’ experience,” according to the company’s Feb. 7 release. Users are instructed to simply add water – which activates DUO’s inner cleanser for a “rich, bubbly lather” – alternate between the puff’s scrubby side and smooth, conditioning side, and then hang the puff to dry when they’re finished. DUO buffers feature the most popular scents from Olay (Soothing Orchid & Black Currant) and Old Spice (Swagger and Pure Sport), as well as a new Ivory scent (Refreshing Clean). They sell in mass retail doors and online for $9.99 to $12.99.

Unilever’s Dove unit is gunning for Procter & Gamble Co.’s Head & Shoulders outfit with the launch of a DermaCare...

HBW Podcast

Explore how consumer health is evolving. On the go.

David Ridley hosts in-depth conversations with industry leaders.

More from Archive

Non-US Approvals - Clone

Devices authorized for marketing outside the US. Data derived from Citeline’s Meddevicetracker. Updated weekly.

Patient access to unapproved medical products allowed under DeFazio, Daschle bills.

 
• By 

PATIENT ACCESS TO UNAPPROVED MEDICAL PRODUCTS WOULD BE ALLOWED under legislation introduced by Rep. Peter DeFazio (D-Ore.) on July 12 and Sen. Tom Daschle (D-S.D.) on July 14. Called the Access to Medical Treatment Act, the legislation would allow health practitioners to administer unapproved drugs, devices, foods or dietary supplements to patients as long as there is no evidence the treatment causes harm and the patient is informed about the treatment and its possible side effects. DeFazio's bill is identified as HR 2019; Daschle's version will be assigned a bill number the week of July 17.

ADHD Medications and Cardiovascular Effects: New Data Revealed. (A Comprehensive Evaluation of Emerging Clinical and Epidemiological Evidence on the Cardiovascular Effects Associated with Commonly Prescribed Medications for Attention Deficit Hyperactivity Disorder)

 
• By 

A look at new research on the cardiovascular effects of ADHD medications and what it means for clinical care. This article explores the latest clinical and epidemiological research on the cardiovascular effects of medications commonly prescribed for ADHD, examining potential heart-related risks, underlying mechanisms, and their implications for patient safety, clinical decision-making, and long-term treatment strategies across diverse age groups and risk profiles.

More from HBW Insight

data

Type:DataArticle | Publication:HBW | Section:Health | Paywall:Premium — Article containing all Composer content for testing (Do not update)

 
• By 

To make your document look professionally produced, Word provides header, footer, cover page, and text box designs that complement each other. For example, you can add a matching cover page, header, and sidebar. Click Insert and then choose the elements you want from the different galleries.

Test: PDF Link Lifetime

Description description

headline test

description